{"disease":{"id":"systemic-amyloidosis","name":"systemic amyloidosis"},"drugs":{"marketed":[{"drug_id":"daratumumab","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex","generic_name":"daratumumab","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD38","drug_class":"Monoclonal antibody","quality_score":10,"revenue":"11800","mechanism":"Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP."},{"drug_id":"cyclophosphamide","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"hyaluronidase","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":10,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"velcade","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Velcade","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bortezomib","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velcade","generic_name":"bortezomib","company_name":"Shilpa","drug_phase":"marketed","molecular_target":"26S proteasome chymotrypsin-like activity","drug_class":"Proteasome inhibitor","quality_score":76,"revenue":null,"mechanism":"Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation."},{"drug_id":"chembl-chembl1200796","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"darzalex","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darzalex","company_name":"Shanghai Henlius Biotech","drug_phase":"marketed","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cyclophosphamid","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06887283","title":"Essen Amyloidosis Registry","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT06292780","title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT01659658","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05150353","title":"Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Ramsay Générale de Santé","has_results":false},{"nct_id":"NCT06803082","title":"The Impact of Systemic Light Chain Amyloidosis on Eyes","phase":"","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06186167","title":"Amyloidosis Incidence in High-Risk Cardiac Device Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Midwest Heart & Vascular Specialists","has_results":false},{"nct_id":"NCT03678259","title":"124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"University of Tennessee Graduate School of Medicine","has_results":false},{"nct_id":"NCT06627309","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03499808","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT01849783","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Margarida Magalhaes-Silverman","has_results":true},{"nct_id":"NCT06192979","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","phase":"NA","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Jin Lu, MD","has_results":false},{"nct_id":"NCT02207556","title":"Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT04006223","title":"The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07151690","title":"BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05968846","title":"Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"University of Tennessee Graduate School of Medicine","has_results":false},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}